Medical reviews published in 2017 and 2018 incorporating numerous clinical trials concluded that cannabidiol is an effective treatment for certain types of childhood epilepsy. An orally administered cannabidiol solution (brand name Epidiolex) was approved by the US Food and Drug Administration in June 2018 as a treatment for two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
It is for this reason that all the finished hemp goods that you see for sale in America, from food products to clothing to building materials, are part of an imported hemp industry that has surpassed $688 million annually. The size of this import industry is one of the major catalysts for hemp legalization in the U.S. As a renewable source of a range of products, hemp provides an exciting new step in American agriculture.
CBD has noted effects on many systems the brain uses to send signals to your body. One of these is the endocannabinoid system. When used, CBD can have beneficial effects on people who suffer neurological disorders. The research in this area is still new. However, there were many studies where CBD was tested for its effect on treating MS and epilepsy.
“CBD is the most promising drug that has come out for neuropsychiatric diseases in the last 50 years,” said Dr. Esther Blessing, an assistant professor at New York University School of Medicine, who is coordinating a study of CBD as a treatment for post-traumatic stress disorder and alcohol use disorder. “The reason it is so promising is that it has a unique combination of safety and effectiveness across of very broad range of conditions.”
At cbdMD, we combine premium quality and innovation to offer the purest CBD available on the market. We test our broad-spectrum CBD extractions through independent, third-party laboratories to guarantee the highest of standards. cbdMD is committed to providing the best in CBD; we stand behind the quality of our products by offering an easy-to-use service, free shipping, satisfaction guarantees, and US-based customer service.
Cannabidiol is currently a class B1 controlled drug in New Zealand under the Misuse of Drugs Act. It is also a prescription medicine under the Medicines Act. In 2017 the rules were changed so that anyone wanting to use it could go to the Health Ministry for approval. Prior to this, the only way to obtain a prescription was to seek the personal approval of the Minister of Health.